Pharmacological treatment of established rheumatoid arthritis

Best Practice and Research: Clinical Rheumatology

Volumn 17, Issue 5, 2003, Pages 811-829

  Lee, Susan Juh Ah ^a   Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biological; Cyclo oxygenase 2 inhibitors; DMARDs; IL I ra; NSAIDs; Pharmacotherapy; Rheumatoid arthritis; TNF inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; ETANERCEPT; FOLIC ACID; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR; ROFECOXIB; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROQUININE;

ACNE; ADJUVANT CHEMOTHERAPY; AGRANULOCYTOSIS; ALOPECIA; ANALGESIC ACTIVITY; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; ASPERGILLOSIS; ATHEROSCLEROSIS; ATYPICAL MYCOBACTERIOSIS; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CYTOPENIA; DEMYELINATING DISEASE; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DOSE CALCULATION; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOXICITY; ELECTROLYTE DISTURBANCE; EMOTIONAL DISORDER; FATTY LIVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEADACHE; HEALTH CARE COST; HEART INFARCTION; HELICOBACTER INFECTION; HIGH RISK PATIENT; HIRSUTISM; HISTOPLASMOSIS; HUMAN; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPERTENSION; INFECTION; INJECTION PAIN; INJECTION SITE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LISTERIOSIS; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; LUNG FIBROSIS; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MOON FACE; MOUTH ULCER; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PANCREATITIS; PATIENT CARE; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PURPURA; RADIOGRAPHY; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; SIDE EFFECT; SKIN ATROPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT PLANNING; TUBERCULOSIS; ULCER; WEIGHT GAIN; FIBROSING ALVEOLITIS; MENTAL INSTABILITY; PLATELET INHITION; RASH; STOMACH DISEASE;

EID: 0042928288     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6942(03)00048-2     Document Type: Review

References (86)

1. Fuchs HA, Kaye JJ, Callahan LF et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. Journal of Rheumatology 1989; 16: 585-591.
2. Van Der Heijde DM, Van Leeuwen MA, Van Riel PL & Van De Putte LB. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (Van Der Heijde modification). Journal of Rheumatology 1995; 22: 1792-1796.
3. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. The Lancet 1997; 350: 309-318.
4. Case JP. Old and new drugs used in rheumatoid arthritis: A historical perspective. Part I: Older drugs. American Journal of Therapeutics 2001; 8: 123-143.
5. Brooks PM. Clinical management of rheumatoid arthritis. The Lancet 1992; 341: 286.
6. Kang RY, Freire-Moar J, Sigal E & Chu CQ. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. British Journal of Rheumatology 1996; 35: 611-718.
7. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine 2000; 343: 1520-1528.
8. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. Journal of the American Medical Association 2000; 284: 1247-1255.
9. Chan FK, Hung LC, Suen BY et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. New England Journal of Medicine 2002; 347: 2104-2110.
10. Baigent C & Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease. Arthritis and Rheumatism 2003; 48: 12-20.
11. Howes LG & Krum H. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction. How strong is the link? Drug Safety 2002; 25: 829-835.
12. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. New England Journal of Medicine 1995; 333: 142-146.
13. Landewé M, Boers M, Verhoeven AC et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis and Rheumatism 2002; 46: 347-356.
14. Moreland LW & O'Dell JR. Glucocorticoids and rheumatoid arthritis. Back to the future? Arthritis and Rheumatism 2002; 46: 2553-2563.
15. Pincus T, O'Dell JR & Kremer J. Combination therapy with multiple disease-modifying anti-rheumatic drugs in rheumatoid arthritis: A preventive strategy. Annals of Internal Medicine 1999; 131: 768-774.
16. Jessop JD, O'Sullivan MM, Lewis PA et al. A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. British Journal of Rheumatology 1998; 37: 992-1002.
17. Clark P, Casas E, Tugwell P et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Annals of Internal Medicine 1993; 119: 1067-1071.
18. Faarvang KL, Egsmose C, Kryger P et al. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: A randomized double blind trial. Annals of Rheumatic Diseases 1993; 52: 711-715.
19. Van Der Heijde DM, Van Riel PL, Nuver-Zwart IH et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. The Lancet 1989; 1: 1036-1038.
20. Felson DT, Anderson JJ & Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthritis and Rheumatism 1990; 33: 1449-1461.
21. Marmor MF, Carr RE, Easterbrook M et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2002; 109: 1377-1382.
22. Van Rijthoven AW, Kijkmans BA, Goeithe HS et al. Cyclosporin treatment for rheumatoid arthritis: A placebo controlled, double blind, multicentre study. Annals of the Rheumatic Diseases 1986; 45: 726-731.
23. Dougados M, Awada H & Amor B. Cyclosporin in rheumatoid arthritis: A double blind, placebo controlled study in 52 patients. Annals of the Rheumatic Diseases 1988; 47: 127-133.
24. Tugwell P, Bombardier C, Gent M et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. The Lancet 1990; 335: 1051-1055.
25. Drosos AA, Voulgari PV, Papadopoulos IA et al. Cyclosporin A in the treatment of early rheumatoid arthritis. A prospective, randomized 24-month study. Clinical and Experimental Rheumatology 1998; 16: 695-701.
26. Case JP. Old and new drugs used in rheumatoid arthritis: A historical perspective. Part 2: The newer drugs and drug strategies. American Journal of Therapeutics 2001; 8: 163-179.
27. Stolk JN, Boerbooms AMT, De Abreu RA et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis and Rheumatism 1998; 41: 1858-1866.
28. Woodland I, Chaput De Saintonge DM, Evans SJ et al. Azathioprine in rheumatoid arthritis: Double-blind study of full versus half dose versus placebo. Annals of the Rheumatic Diseases 1981; 40: 355-359.
29. Willkens RF, Urowitz MB, Stablein DM et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism 1992; 35: 1799-1806.
30. Jeurissen MEC, Boerbooms AMT, Van De Putte LBA et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: A forty-eight week randomized, double-blind trial. Arthritis and Rheumatism 1991; 34: 961-972.
31. Hamdy H, McKendry RJR, Mierins E & Liver RJA. Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. Arthritis and Rheumatism 1987; 30: 361-368.
32. Kavanaugh AF & Lipsky PE. Disease-modifying antirheumatic drugs. Drugs of Today 1993; 29: 431-445.
33. Sinclair RJG & Duthie JJR. Salazopyrin in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases 1948; 8: 226-231.
34. McConkey B, Amos RS, Durham S et al. Sulphasalazine in rheumatoid arthritis. British Medical Journal 1980; 1: 442-444.
35. Pinals RS, Kaplan SB, Lawson JG & Hepburn B. Sulfasalazine in rheumatoid arthritis. Arthritis and Rheumatism 1986; 29: 1427-1434.
36. Box SA & Pullar T. Sulphasalazine in the treatment of rheumatoid arthritis. British Journal of Rheumatology 1997; 36: 382-386.
37. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. New England Journal of Medicine 1985; 312: 818-822.
38. Weinblatt ME, Trentham DE, Fraser PA et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis and Rheumatism 1988; 31: 167-175.
39. Williams JH, Willkens RF, Samuelson CO et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. Arthritis and Rheumatism 1985; 28: 721-730.
40. Weinblatt ME, Weissman BN, Holdworth DE et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis and Rheumatism 1992; 35: 129-137.
41. Weinblatt ME, Kaplan H, Germain BF et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis and Rheumatism 1994; 37: 1492-1498.
42. Kremer JM & Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis and Rheumatism 1992; 35: 138-145.
43. Morgan SL, Baggott JE, Vaughn WH et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism 1990; 33: 9-18.
44. Morgan SL, Baggot JE, Vaughn WH et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: A double-blind, placebo-controlled trial. Annals of Internal Medicine 1994; 121: 833-841.
45. Van Ede AE, Laan RF, Food MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis and Rheumatism 2001; 44: 1515-1524.
46. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Archives of Internal Medicine 1999; 159: 2542-2550.
47. Emery P, Breedveld FC, Lemmel EM et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000; 39: 655-665.
48. European Leflunomide Study Group. Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomized, multicenter trial. The Lancet 1999; 353: 259-266.
49. Rozman B. Clinical pharmacokinetics of leflunomide. Clinical Pharmacokinetics 2002; 41: 421-430.
50. Mottonen T, Hannonen P, Leirisalo-Repo M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. The Lancet 1999; 353: 1568-1573.
51. Tugwell P, Pincus T, Yocum D et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. New England Journal of Medicine 1995; 333: 137-141.
52. Kremer JM, Genovese MC, Cannon GW et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. Annals of Internal Medicine 2002; 137: 726-733.
53. Weinblatt ME, Kremer JM, Coblyn JS et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis and Rheumatism 1999; 42: 1322-1328.
54. O'Dell JR, Haire CE & Erikson N. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. New England Journal of Medicine 1996; 334: 1287-1291.
55. Haagsma CJ, Vaan Riel PL, De Jong AJ et al. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology 1997; 36: 1082-1088.
56. Abramson SB & Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology 2002; 41: 972-980.
57. Criscione LG & St. Clair EW. Tumor necrosis factor-α antagonists for the treatment of rheumatic diseases. Current Opinion in Rheumatology 2002; 14: 204-211.
58. Shanahan J & St. Clair EW. Short analytical review, tumor necrosis factor-α blockade: A novel therapy for rheumatic disease. Clinical Immunology 2002; 103: 231-242.
59. Furst DE, Keystone EC, Breedveld FC et al. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). Annals of the Rheumatic Diseases 2001; 60(Suppl.):iii2-iii5.
60. Wallis WJ, Burge DJ, Sabath D et al. Tuberculosis reports with etanercept therapy. Arthritis and Rheumatism 2001; 44(Suppl.):S78.
61. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. New England Journal of Medicine 2001; 345: 1098-1104.
62. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis tumor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis and Rheumatism 1998; 41: 1552-1563.
63. Maini R, St. Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumor necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial. The Lancet 1999; 354: 1932-1939.
64. Lipsky PE, Van Der Heijde DF, St. Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. New England Journal of Medicine 2000; 343: 1594-1602.
65. Lipsy P, St. Clair W, Kavanaugh A et al. Long-term control of signs and symptoms of rheumatoid arthritis with chimeric monoclonal anti-TNF-a antibody (infliximab) in patients with active disease on methotrexate. Arthritis and Rheumatism 1998; 31: S364.
66. Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New England Journal of Medicine 1997; 337: 141-147.
67. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Annals of Internal Medicine 1999; 130: 478-486.
68. Weinblatt ME, Kremer JM, Bankhurst AD et al. Trial of etanercept, a recombinant tumor necrosis factor receptor: Fc Fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New England Journal of Medicine 1999; 340: 253-259.
69. Genovese MC, Bathon JM, Martin R et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two year radiographic and clinical outcomes. Arthritis and Rheumatism 2002; 46: 1443-1450.
70. Kempeni J. Update on D2E7: A fully human anti-tumour necrosis factor α monoclonal antibody. Annals of the Rheumatic Diseases 2000; 59(Suppl. I): i44-i45.
71. Raur R. Adalimumab (a fully human anti-tumour necrosis factor α monoclonal antibody) in the treatment of active rheumatoid arthritis: The initial results of five trials. Annals of the Rheumatic Diseases 2002; 61(Suppl. II): ii70-ii73.
72. Van Den Putte LBA, Rau R, Breedveld FC et al. Six month efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis. Annals of the Rheumatic Diseases 2000; 59(Suppl. I): i47.
73. Weinblatt ME, Keystone EC & Furst DE. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis and Rheumatism 2003; 48: 35-45.
74. Schiff MH. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Annals of the Rheumatic Diseases 2000; 59(Suppl. I): i103-i108.
75. Nuki G, Bresnihan B, Bear MB & McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis. Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 2002; 46: 2838-2846.
76. Arend WP. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: The role of interleukin-1 receptor antagonist. Seminars in Arthritis and Rheumatism 2001; 30(Suppl. 2): 1-6.
77. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis and Rheumatism 1998; 41: 2196-2204.
78. Jiang Y, Genant HK, Watt I et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis and Rheumatism 2000; 43: 1001-1009.
79. Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis and Rheumatism 2002; 26: 614-624.
80. Breshnihan B: Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis. Annals of the Rheumatic Diseases 2002; 61(Suppl. II): ii74-ii77.
81. Moreland LW, Alten R, Van Den Bosch F et al. Costimulatory blockade in patients with rheumatoid arthritis. Arthritis and Rheumatism 2002; 46: 1470-1479.
82. Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA41g-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. Journal of Clinical Investigation 1999; 103: 1243-1252.
83. Webb LM, Walmsley MJ & Feldman M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: Requirement for both B7-1 and B7-2. European Journal of Immunology 1996; 26: 2320-2328.
84. De Vita S, Saja F, Sacco S et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Arthritis and Rheumatism 2002; 46: 2029-2933.
85. Leandro MJ, Edwards JC & Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Annals of the Rheumatic Diseases 2002; 61: 883-888
86. Zaja F, Iacona I, Masolini P. et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002; 87: 189-195.